Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases

Table 5 Trials assessing the effect of VSL#3 in patients with non-alcoholic fatty liver disease

Ref.	Design	n	VSL#3 intake
Loguercio et al[109], 2005	Not mentioned	78 patients: 22 with NAFLD, 20 with alcoholic cirrhosis, 20 with HCV-related chronic hepatitis, and 16 with HCV-related cirrhosis	3 mo, the daily dose was not clear
Alisi et al[110], 2014	RCT	48 randomized children; 44 (22 with VSL#3 and 22 with placebo) completed the study	4 mo with 1 sachet a day (less than 10 yr old) or 2 sachets a day (older than 10 yr old)
Miccheli et al[111], 2015	RCT	31 pediatric NAFLD patients	4 mo with 1 sachet a day (less than 10 yr old) or 2 sachets a day (older than 10 yr old)

NAFLD: Non-alcoholic fatty liver disease; HCV: Hepatitis C virus; RCT: Randomized controlled trial.